The Richest Woman in the World: How Gina Rinehart Earns her Billions
Why Dell Will Never Be Great Again"Right now I'm having a love affair with Amylin Pharmaceuticals Inc. (NASDAQ: AMLN); frankly, you should be in love with it, too." says Michael Shulman, editor of the industry-leading ChangeWave Biotech Investor.
The advisor notes, "Not only is it up a whopping 169%+ since I put it on the Buy List, it's also a hidden-value play -- more so than at any time in the past year. Simply put, Amylin is a great pick for patient investors."
Shulman continues, "Amylin no longer appears sexy or hot to some investors. It has a market cap north of $5 billion and its two newest drugs have been on the market for a couple of years, so the story on the stock appears to be over in terms of upside potential, right?
"Wrong," he exclaims. "Amylin is going to benefit in the coming months from a string of good news, beginning with the strong earnings it announced two weeks ago. The diabetes marketplace is exploding and Amylin is 'the' leading diabetes company."
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
